The ACA individual exchange exit is positioned as a strategic de-emphasis of a shrinking line, with no 2026 network changes ...

Medicare Advantage 2027 updates boost payment updates near 5%, but risk rules and prior auth reforms force plans to rethink ...

HealthDyne has 50,000 lives running through its direct-to-employer model but is eyeing a future of many more, according to ...

HealthDyne’s Sarah Thomas and David Skomo say that direct-to-patient arrangements eliminate opacity in drug pricing and allow ...

The pharmaceutical industry is entering an era of mega-blockbusters, drugs with annual sales of $10 billion or more, that ...

A high-touch specialty pharmacy program that combines pharmacist support, telehealth and value-based care reduced medical ...

Skomo, chief operating officer for HealthDyne, and Thomas, head of growth and commercialization, led a session today about ...

Frequent CGM use ties to bigger A1c drops in type 2 diabetes, even across GLP-1, SGLT2, and insulin regimens. In this episode ...

PSG’s research found that payers are placing more attention on specialty drugs covered under the medical benefit, showing ...

The 340B Drug Pricing Program has become a central force in the U.S. drug market, allowing certain hospitals and clinics to ...

Bispecific antibodies are currently approved as late-line therapy, but they are moving up to earlier lines “as they prove ...

Provider groups, especially community oncologists, are worried that drug prices negotiated under the IRA will drastically ...